Gritstone Oncology, Inc. (GRTS)
Stock Price:
$2.91 USD
-0.03 (-1.02%)
Updated Oct 27, 2020 1:15 PM EDT - Market open
Key Info
| Market Cap |
109.85M |
| Revenue (ttm) |
3.62M |
| Net Income (ttm) |
-107.33M |
| Shares Out |
37.75M |
| EPS (ttm) |
-2.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$2.91 |
| Previous Close |
$2.94 |
| Change ($) |
-0.03 |
| Change (%) |
-1.02% |
| Day's Open |
2.91 |
| Day's Range |
2.90 - 2.98 |
| Day's Volume |
43,796 |
| 52-Week Range |
2.60 - 12.96 |
More Stats
| Market Cap |
109.85M |
| Enterprise Value |
44.43M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
37.75M |
| Float |
24.26M |
| EPS (basic) |
-2.94 |
| EPS (diluted) |
-2.95 |
| FCF / Share |
-2.82 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.34M |
| Short Ratio |
5.83 |
| Short % of Float |
9.64% |
| Beta |
1.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
30.36 |
| PB Ratio |
1.18 |
| Revenue |
3.62M |
| Operating Income |
-109.53M |
| Net Income |
-107.33M |
| Free Cash Flow |
-105.15M |
| Net Cash |
65.42M |
| Net Cash / Share |
1.73 |
| Gross Margin |
-2,170.56% |
| Operating Margin |
-3,027.22% |
| Profit Margin |
-2,966.40% |
| FCF Margin |
-2,906.25% |
| ROA |
-36.62% |
| ROE |
-77.05% |
| ROIC |
-101.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
3 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.75*
(303.78% upside)
Low
6.00
Current: $2.91
High
17.00
Target: 11.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 4.37 | 1.19 | - | - |
| Revenue Growth | 267.73% | - | - | - |
| Gross Profit | 4.37 | 1.19 | - | - |
| Operating Income | -97.94 | -65.58 | -41.76 | -18.98 |
| Net Income | -94.43 | -64.78 | -41.38 | -18.75 |
| Shares Outstanding | 33.55 | 8.92 | 2.00 | 1.67 |
| Earnings Per Share | -2.81 | -7.26 | -20.70 | -11.21 |
| Operating Cash Flow | -85.01 | -38.16 | -34.97 | -15.29 |
| Capital Expenditures | -16.17 | -5.66 | -11.49 | -6.98 |
| Free Cash Flow | -101 | -43.83 | -46.46 | -22.28 |
| Cash & Equivalents | 128 | 153 | 85.95 | 37.51 |
| Total Debt | 23.49 | 10.49 | 10.52 | - |
| Net Cash / Debt | 104 | 143 | 75.43 | 37.51 |
| Assets | 184 | 190 | 117 | 46.42 |
| Liabilities | 50.05 | 40.44 | 20.02 | 4.73 |
| Book Value | 134 | 149 | 97.28 | 41.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Gritstone Oncology, Inc. |
| Country |
United States |
| Employees |
176 |
| CEO |
Andrew R. Allen |
Stock Information
| Ticker Symbol |
GRTS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GRTS |
| IPO Date |
September 28, 2018 |
Description
Gritstone Oncology, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.